Prescriptions of Strong Opioid Analgesics in Primary Care (Pharmacy Care)

Abstract

Every person experiences pain at some point, and persistent pain is a common symptom of illnesses like cancer. Opioid
analgesics have a crucial role in the treatment of persistent cancer pain. This study looked back at VITAE-approved
prescriptions for powerful opioid analgesics from January through March of 2015. Adult patients at the Oncology
Institute in Kosice were given powerful analgesic prescriptions. All individuals analyzed who were prescribed opioids
had a diagnosis of cancer. Retrospective assessments of prescriptions looked at patient demographics, cancer diagnosis,
and the generic and brand versions of opioid analgesics provided to treat pain. The research found that throughout the
study period, the East-Slovak Oncology Institute in Koice, Slovakia, prescribed 332 doses of powerful opioids to 151
patients (54% male; 46% female) with cancer. Female patients ranged in age from 27 to 88, with 27 being the youngest.
Males were most often diagnosed with lung and thoracic cancer, while females were most often diagnosed with breast
cancer. The total quantity of packagesFentanyl (44%), buprenorphine (26%), oxycodone (12%), tapentadol (10%), and
morphine (7%) accounted for 543 of the powerful opioids. Our data showed that other opioids such as fentanyl,
buprenorphine, oxycodone, and the novel chemical tapentadol are given more often than morphine, despite morphine's
continued status as the gold standard in oncologic pain management. All of these drugs were recommended to alleviate
excruciating pain brought on by various stages of tumor growth.